CardioCovidV1, Main, Corpus, bibRecord, 000169

Oncocardiology: new challenges, new opportunities.

Identifieur interne : 000169 ( Main/Corpus ); précédent : 000168; suivant : 000170

Oncocardiology: new challenges, new opportunities.

Auteurs : Lars Michel ; Dirk Schadendorf ; Tienush Rassaf

Source :

Herz [ 1615-6692 ] ; 2020.

RBID : pubmed:32514587

Abstract

Patients with cancer are at a higher risk of cardiovascular disease, which contributes to significant morbidity and mortality. The rapid progress in the field of oncological treatments has led to a steady increase in long-term cancer survivors. Care for cardiovascular complications is therefore becoming increasingly important. In addition, the establishment of new oncological therapies has resulted in the identification of previously unknown cardiovascular side effects. Oncocardiology aims to detect and treat cardiovascular diseases associated with cancer and cancer therapy. Continuous scientific, clinical, and structural developments are necessary as the basis for the best care of the growing number of affected patients. This review summarizes current developments in the field of oncocardiology with regard to advances in cancer therapy and challenges in clinical oncocardiology work. Cardiovascular side effects by targeted cancer therapies are characterized and recent advances in the field of cardiovascular diagnostics are outlined. Developments to better integrate oncocardiology into the medical care system and perspectives for modern, patient-oriented care are shown. In light of the coronavirus disease 2019 (COVID-19) pandemic, current challenges and opportunities are highlighted. The relevance of profitable further advances in oncocardiology including standardized guidelines and educational programs is delineated as a mandatory requirement for the successful development of oncocardiology.

DOI: 10.1007/s00059-020-04951-x
PubMed: 32514587
PubMed Central: PMC7278757

Links to Exploration step

pubmed:32514587

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Oncocardiology: new challenges, new opportunities.</title>
<author><name sortKey="Michel, Lars" sort="Michel, Lars" uniqKey="Michel L" first="Lars" last="Michel">Lars Michel</name>
<affiliation><nlm:affiliation>Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, Medical Faculty, University Hospital Essen, Hufelandstraße 55, 45147, Essen, Germany.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Schadendorf, Dirk" sort="Schadendorf, Dirk" uniqKey="Schadendorf D" first="Dirk" last="Schadendorf">Dirk Schadendorf</name>
<affiliation><nlm:affiliation>Department of Dermatology, University Hospital Essen, Hufelandstraße 55, 45147, Essen, Germany.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Partner Site Essen/Düsseldorf, German Cancer Consortium (DKTK), 45147, Essen, Germany.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Rassaf, Tienush" sort="Rassaf, Tienush" uniqKey="Rassaf T" first="Tienush" last="Rassaf">Tienush Rassaf</name>
<affiliation><nlm:affiliation>Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, Medical Faculty, University Hospital Essen, Hufelandstraße 55, 45147, Essen, Germany. Tienush.Rassaf@uk-essen.de.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32514587</idno>
<idno type="pmid">32514587</idno>
<idno type="doi">10.1007/s00059-020-04951-x</idno>
<idno type="pmc">PMC7278757</idno>
<idno type="wicri:Area/Main/Corpus">000169</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000169</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Oncocardiology: new challenges, new opportunities.</title>
<author><name sortKey="Michel, Lars" sort="Michel, Lars" uniqKey="Michel L" first="Lars" last="Michel">Lars Michel</name>
<affiliation><nlm:affiliation>Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, Medical Faculty, University Hospital Essen, Hufelandstraße 55, 45147, Essen, Germany.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Schadendorf, Dirk" sort="Schadendorf, Dirk" uniqKey="Schadendorf D" first="Dirk" last="Schadendorf">Dirk Schadendorf</name>
<affiliation><nlm:affiliation>Department of Dermatology, University Hospital Essen, Hufelandstraße 55, 45147, Essen, Germany.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Partner Site Essen/Düsseldorf, German Cancer Consortium (DKTK), 45147, Essen, Germany.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Rassaf, Tienush" sort="Rassaf, Tienush" uniqKey="Rassaf T" first="Tienush" last="Rassaf">Tienush Rassaf</name>
<affiliation><nlm:affiliation>Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, Medical Faculty, University Hospital Essen, Hufelandstraße 55, 45147, Essen, Germany. Tienush.Rassaf@uk-essen.de.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Herz</title>
<idno type="eISSN">1615-6692</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Patients with cancer are at a higher risk of cardiovascular disease, which contributes to significant morbidity and mortality. The rapid progress in the field of oncological treatments has led to a steady increase in long-term cancer survivors. Care for cardiovascular complications is therefore becoming increasingly important. In addition, the establishment of new oncological therapies has resulted in the identification of previously unknown cardiovascular side effects. Oncocardiology aims to detect and treat cardiovascular diseases associated with cancer and cancer therapy. Continuous scientific, clinical, and structural developments are necessary as the basis for the best care of the growing number of affected patients. This review summarizes current developments in the field of oncocardiology with regard to advances in cancer therapy and challenges in clinical oncocardiology work. Cardiovascular side effects by targeted cancer therapies are characterized and recent advances in the field of cardiovascular diagnostics are outlined. Developments to better integrate oncocardiology into the medical care system and perspectives for modern, patient-oriented care are shown. In light of the coronavirus disease 2019 (COVID-19) pandemic, current challenges and opportunities are highlighted. The relevance of profitable further advances in oncocardiology including standardized guidelines and educational programs is delineated as a mandatory requirement for the successful development of oncocardiology.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32514587</PMID>
<DateRevised><Year>2020</Year>
<Month>06</Month>
<Day>12</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1615-6692</ISSN>
<JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year>
<Month>Jun</Month>
<Day>08</Day>
</PubDate>
</JournalIssue>
<Title>Herz</Title>
<ISOAbbreviation>Herz</ISOAbbreviation>
</Journal>
<ArticleTitle>Oncocardiology: new challenges, new opportunities.</ArticleTitle>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s00059-020-04951-x</ELocationID>
<Abstract><AbstractText>Patients with cancer are at a higher risk of cardiovascular disease, which contributes to significant morbidity and mortality. The rapid progress in the field of oncological treatments has led to a steady increase in long-term cancer survivors. Care for cardiovascular complications is therefore becoming increasingly important. In addition, the establishment of new oncological therapies has resulted in the identification of previously unknown cardiovascular side effects. Oncocardiology aims to detect and treat cardiovascular diseases associated with cancer and cancer therapy. Continuous scientific, clinical, and structural developments are necessary as the basis for the best care of the growing number of affected patients. This review summarizes current developments in the field of oncocardiology with regard to advances in cancer therapy and challenges in clinical oncocardiology work. Cardiovascular side effects by targeted cancer therapies are characterized and recent advances in the field of cardiovascular diagnostics are outlined. Developments to better integrate oncocardiology into the medical care system and perspectives for modern, patient-oriented care are shown. In light of the coronavirus disease 2019 (COVID-19) pandemic, current challenges and opportunities are highlighted. The relevance of profitable further advances in oncocardiology including standardized guidelines and educational programs is delineated as a mandatory requirement for the successful development of oncocardiology.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Michel</LastName>
<ForeName>Lars</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, Medical Faculty, University Hospital Essen, Hufelandstraße 55, 45147, Essen, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Schadendorf</LastName>
<ForeName>Dirk</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Department of Dermatology, University Hospital Essen, Hufelandstraße 55, 45147, Essen, Germany.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Partner Site Essen/Düsseldorf, German Cancer Consortium (DKTK), 45147, Essen, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Rassaf</LastName>
<ForeName>Tienush</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, Medical Faculty, University Hospital Essen, Hufelandstraße 55, 45147, Essen, Germany. Tienush.Rassaf@uk-essen.de.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<VernacularTitle>Onkokardiologie: Neue Herausforderungen, neue Möglichkeiten.</VernacularTitle>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>06</Month>
<Day>08</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Germany</Country>
<MedlineTA>Herz</MedlineTA>
<NlmUniqueID>7801231</NlmUniqueID>
<ISSNLinking>0340-9937</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword>
<Keyword MajorTopicYN="N">Cancer</Keyword>
<Keyword MajorTopicYN="N">Cardiotoxicity</Keyword>
<Keyword MajorTopicYN="N">Cardiovascular disease</Keyword>
<Keyword MajorTopicYN="N">Imaging</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>6</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>6</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>6</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>aheadofprint</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32514587</ArticleId>
<ArticleId IdType="doi">10.1007/s00059-020-04951-x</ArticleId>
<ArticleId IdType="pii">10.1007/s00059-020-04951-x</ArticleId>
<ArticleId IdType="pmc">PMC7278757</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Circulation. 2018 Aug 14;138(7):678-691</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29459363</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cardiovasc Hematol Disord Drug Targets. 2020;20(1):74-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31513000</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br J Haematol. 2016 Nov;175(3):462-466</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27611233</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur Heart J. 2016 Sep 21;37(36):2768-2801</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27567406</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Cardiol Heart Vasc. 2019 Sep 07;25:100420</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31517036</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Am Heart Assoc. 2017 Aug 10;6(8):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28862931</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JACC CardioOncol. 2020 Apr 22;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32328590</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Semin Nephrol. 2010 Nov;30(6):591-601</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21146124</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cardiooncology. 2019 Sep 2;5:12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32154018</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Leuk Lymphoma. 2018 Nov;59(11):2557-2569</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29465266</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Nucl Cardiol. 2019 Nov 25;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31768901</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Cardiol. 2019 Apr 1;280:163-175</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30661849</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2019 Feb 14;133(7):710-723</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30482794</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Netw Open. 2019 Aug 2;2(8):e198890</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31397860</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Oncol. 2018 Sep;19(9):e447-e458</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30191849</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 May 2;395(10234):1417-1418</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32325026</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Oncology (Williston Park). 2016 Nov 15;30(11):970-4, 980-1, C3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27848243</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2019 Jun;25(6):936-940</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31171879</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2019 Aug 1;381(5):432-443</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31365801</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2019 Nov 28;134(22):1919-1928</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31582362</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood Cancer J. 2017 Dec 13;7(12):642</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29234003</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Oncol. 2018 Mar 8;4(3):e174519</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29285538</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JACC CardioOncol. 2020 Apr 10;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32292919</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Med Res. 2019 Jan 3;24(1):1</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30606260</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JACC Clin Electrophysiol. 2018 Dec;4(12):1491-1500</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30573111</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Saudi Med. 2016 Jan-Feb;36(1):78-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26922692</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Cancer. 2014 Dec 04;14:915</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25471129</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Heart Fail. 2014 Mar;16(3):300-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24464946</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Nucl Cardiol. 2019 Oct 2;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31578659</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Thorac Dis. 2018 Dec;10(Suppl 35):S4282-S4295</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30701097</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2014 Nov 13;371(20):1877-88</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25265492</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Heart Fail. 2020 Feb;22(2):350-361</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31721381</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Heart Fail Rev. 2020 Mar 3;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32128669</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Cardiol. 2020 May;17(5):259-260</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32139904</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cardiovasc Drugs Ther. 2017 Feb;31(1):63-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28185035</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CardioCovidV1/Data/Main/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000169 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000169 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CardioCovidV1
   |flux=    Main
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:32514587
   |texte=   Oncocardiology: new challenges, new opportunities.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i   -Sk "pubmed:32514587" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a CardioCovidV1

This area was generated with Dilib version V0.6.35.
Data generation: Tue Aug 4 15:08:30 2020. Site generation: Wed Jan 27 11:23:02 2021

	Serveur d'exploration Covid et maladies cardiovasculaires
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Covid et maladies cardiovasculaires

Oncocardiology: new challenges, new opportunities.

Oncocardiology: new challenges, new opportunities.

Source :

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki